A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples